Osage University Partners has backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.
Sonoma Biotherapeutics, a US-headquartered immunotherapy developer, has raised $265m in a series B round featuring spinout-focused venture capital firm Osage University Partners.
The round was led by private equity firm Ally Bridge Group and included Fidelity, ArrowMark Partners, Avidity Partners, Casdin Capital, Deep Track Capital, Frazier Healthcare Partners, Janus Henderson Investors and Mirae Asset.
Piper Heartland Healthcare Capital, Vertex Ventures HC and an undisclosed investment fund also took part, as did 8VC, Arch Venture Partners, the JDRF T1D Fund, LifeForce Capital and Octagon Capital.
Internet and technology group Alphabet invested via its subsidiary GV, while pharmaceutical firms Eli Lilly and Dong-A ST deployed capital through respective investment arms Lilly Asia Ventures Biosciences and NS Investment.
Life sciences real estate investment trust Alexandria Real Estate Equities took part through its corporate venturing unit Alexandria Venture Investments.
Founded in 2019, Sonoma uses genome editing to develop regulatory…
